Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-30 11:50 am Sale |
2025-05-29 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 3,600,000 8.100% |
-733,817 (-16.93%) |
Filing History |
| 2025-05-15 4:10 pm Sale |
2025-03-31 | 13G | Harvard Bioscience, Inc. HBIO |
HARVEY PARTNERS, LLC | 2,187,500 4.960% |
-370,000 (-14.47%) |
Filing History |
| 2025-05-14 12:28 pm Purchase |
2025-05-13 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 4,333,817 9.800% |
563,465 (+14.94%) |
Filing History |
| 2025-05-08 12:45 pm Purchase |
2025-03-31 | 13G | Harvard Bioscience, Inc. HBIO |
Weber Capital Management, LLC | 3,200,380 7.260% |
683,450 (+27.15%) |
Filing History |
| 2025-04-08 09:49 am Purchase |
2025-04-01 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 3,770,352 8.600% |
485,817 (+14.79%) |
Filing History |
| 2025-04-07 4:06 pm Sale |
2025-03-31 | 13G | Harvard Bioscience, Inc. HBIO |
Punch & Associates Investment Management, Inc. | 25,586 0.100% |
-2,892,448 (-99.12%) |
Filing History |
| 2025-03-17 10:33 am Purchase |
2025-03-14 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 3,284,535 7.500% |
1,139,644 (+53.13%) |
Filing History |
| 2025-02-10 4:56 pm Purchase |
2024-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
Weber Capital Management, LLC | 2,516,930 5.770% |
2,516,930 (New Position) |
Filing History |
| 2025-02-04 10:37 am Sale |
2025-02-03 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 2,144,891 4.900% |
-163,731 (-7.09%) |
Filing History |
| 2024-11-14 12:31 pm Sale |
2024-09-30 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 1,555,820 3.600% |
-1,383,458 (-47.07%) |
Filing History |
| 2024-03-19 1:02 pm Purchase |
2024-03-18 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 2,308,622 5.320% |
201,952 (+9.59%) |
Filing History |
| 2024-02-14 4:05 pm Sale |
2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
HARVEY PARTNERS, LLC | 2,557,500 6.000% |
-354,000 (-12.16%) |
Filing History |
| 2024-02-14 09:00 am Purchase |
2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
Punch & Associates Investment Management, Inc. | 2,918,034 6.800% |
153,995 (+5.57%) |
Filing History |
| 2024-02-14 08:46 am Sale |
2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 2,939,278 6.900% |
-325,518 (-9.97%) |
Filing History |
| 2024-02-13 4:01 pm Sale |
2024-01-09 | 13G | HARVARD APPARATUS REGENERATIVE HRGN |
HARVARD BIOSCIENCE INC HBIO |
697,112 5.000% |
-11,404 (-1.61%) |
Filing History |
| 2024-01-26 5:26 pm Purchase |
2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
BlackRock Inc. BLK |
2,913,814 6.800% |
1,704,695 (+140.99%) |
Filing History |
| 2024-01-22 10:55 am Sale |
2024-01-16 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 2,106,670 4.940% |
-52,124 (-2.41%) |
Filing History |
| 2023-08-28 3:07 pm Purchase |
2023-08-25 | 13G | Harvard Bioscience, Inc. HBIO |
Leviticus Partners LP | 2,158,794 5.060% |
104,887 (+5.11%) |
Filing History |
| 2023-02-16 3:11 pm Unchanged |
2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 3,264,796 7.800% |
0 (Unchanged) |
Filing History |
| 2023-02-15 5:30 pm Purchase |
2022-11-29 | 13G | Harvard Bioscience, Inc. HBIO |
272 Capital LP | 3,264,796 7.840% |
3,264,796 (New Position) |
Filing History |